Rodman & Renshaw analyst Elemer Piros initiated coverage of Telomir Pharmaceuticals (TELO) with a Buy rating and $15 price target The firm estimates the net present value of potential cash flows for the company’s Wilson’s disease program through 2044 at $300M or $9 per share. Rodman assigned a $200M, or $6 per share technology value to Telomir-1, reflecting its potential for additional indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1
- Telomir Pharmaceuticals files $150M mixed securities shelf
- Biotech Alert: Searches spiking for these stocks today
- Renovaro BioSciences appoints Fuentes as Chief Financial Officer
- Telomir announces findings from preclinical progeria lifespan study